N/A N=11 Baroreflex Activation Therapy in Heart Failure
Heart Failure
Primary: Changes in Sympathetic Nervous System Activity (MSNA Bursts/Min) — -13.8 bursts/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=124 Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
Cerebral Atherosclerosis
Primary: Change in Mean Value of Lipoprotein Resistance to LPO. — 42.4; 42.9; 55.6; 49.4 seconds — p=0.007
N/A N=11 A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers
Healthy Adults · Skin Enhancement
Primary: Change From Baseline in Skin Hydration as Measured by MoistureMeterD® 0.5 mm — 1.7; -0.0; 1.2; 0.6 tissue dielectric constant — p=0.0736
N/A N=15 Piloting "Positive Peer Journaling" a Journaling Practice to Support Recovery From Addiction
Addiction
Primary: Treatment Retention — 73.3 percentage of participants
Early Phase 1 N=116 OLP-1002 is Being Studied in the Treatment of Pain.
Pain
Primary: Number of Participants With Adverse Events Stratified by Overall and Severity — 7; 3; 2; 0 Participants
Phase 2 N=72 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate — 15; 3; 27; 11 Participants
Phase 2 N=20 The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Ichthyosis · Autosomal Recessive Congenital Ichthyosis · Lamellar Ichthyosis
Primary: Reduction at Week 16 in the Ichthyosis Area Severity Index (IASI) — 2.4; 4.3 units on a scale
Phase 2 N=7 Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Lung Diseases, Interstitial · Systemic Sclerosis · Scleroderma
Primary: Number of Participants With Serious Adverse Events — 0.33; 0.25 Number of Participants with Serious Adve
Phase 2 N=20 Nitrate Effect on Exercise Capacitance
Fontan
Primary: Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period. — 16 Participants
Phase 1 N=14 A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects
Breast Cancer
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period. — 64.85; 381.0; 138.2; 91.83 ng/mL
Phase 3 N=364 Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration
Chronic Pain
Primary: Granulomas — 12; 352; 0; 0 Participants
Phase 3 N=612 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
Foot Ulcer, Diabetic · Infection
Primary: Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 115; 64; 48 Participants
Phase 2 N=149 Aerosolized Surfactant in Neonatal RDS
Respiratory Distress Syndrome, Newborn
Primary: Number of Participants With Adverse Events as a Measure of Safety and Feasibility — 3; 8; 4; 12 Participants
Phase 4 N=59 A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment
Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality
Primary: Change From Baseline in Rasch-transformed Score of FACE-Q Satisfaction With Facial Appearance Overall Scale to End of Study — 40.9; 37.8; 21.5; 32.9 score on a scale…
Phase 2 N=48 A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
Acute Myocardial Infarction
Primary: Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation — 21; 21 Count of participants — p=<0.001